AEG 40826

Drug Profile

AEG 40826

Alternative Names: AEG40826; HGS-1029

Latest Information Update: 20 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aegera Therapeutics
  • Developer Human Genome Sciences; Pharmascience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 20 May 2016 No recent reports on development identified- Phase-I for Solid tumours in Canada (IV)
  • 12 Dec 2012 Pharmascience intends to initiate a phase Ib trial of AEG 40826 in the near future
  • 12 Dec 2012 Pharmascience Inc. regains global rights to AEG 4086 as part of an agreed-upon termination of its oncology collaboration with Human Genome Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top